-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Willingness-to-pay for caregivers of children with asthma or wheezing conditions
(1940) Views (402) Full article downloads
Authors: Stefan Walzer, Peter Zweifel
Published Date February 2007
Volume 2007:3(1) Pages 157 - 165
DOI: http://dx.doi.org/10.2147/TCRM.S
Stefan Walzer1, Peter Zweifel2
1Analytica International, Untere Herrenstrasse 25, 79539 Loerrach, Germany; 2University of Zurich, Socioeconomic Institute, Hottingerstr. 10, 8032 Zurich, Switzerland
Background: Nearly 5 million children in the United States are affected by asthma, which is more than 5% of the population younger than 18 years. In children four years or younger, the prevalence increased 160% from 1980 to 1994. There are several effective drugs that relieve the symptoms of asthma and others are currently being developed, but even when these medications are prescribed, they may be underutilized because parents fear the possibility of adverse events. There is no knowledge whether caregivers would be willing to pay (WTP) for safe and effective medications in general.
Material and methods: In a conjoint analysis, the status quo and hypothetical treatment options are defined by four attributes: episode-free days, risk of exacerbation, information available on the long-term impact of the treatment, and out-of-pocket expenses. Based on random utility theory, a binary purchase decision equation is specified and estimated using probit. Several tests were performed with regards to the scaling of the attribute variables, the linearity of the utility function used, and the derivation of a final model.
Results and conclusions: Marginal willingness-to-pay per month for 20 additional episode-free days due to a new treatment turns out to be US$6.00. An interesting question from the (industry) policy point of view for possible new products is the amount of WTP for the product as a whole. Assuming that the final model is correctly specified, the (negative) constant may be interpreted as indicating that caregivers feel confident with the asthma treatment options already on the market and having hence not a positive relation to a new treatment.
Keywords: willingness-to-pay; conjoint analysis, preference study, health economics, discrete-choice analysis
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Aliskiren in hypertension: evidence for its potential therapeutic value
Management of acute attacks of hereditary angioedema: potential role of icatibant
Inpatient charges and mental illness: Findings from the Nationwide Inpatient Sample 1999–2007
Mediterranean diet and polyamine intake: possible contribution of increased polyamine intake to inhibition of age-associated disease
Questionnaire-based evaluation of everyday competence in older adults
Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision
Career choices among medical students in Bangladesh
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




